Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut

MANGOCEUTICALS, INC.

Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.
Controlled H5N1 challenge (ICAR-NIHSAD): 48-hr pre-treatment reduced mortality 60% (2/7 vs 5/7 deaths) and extended mean time to death to 10.71 days.
Surviving birds in H5N1 study were seronegative for H5 antibodies at day 14, suggesting early interference with infection establishment.
MGX-0024 is a GRAS-classified polyphenol/zinc formulation forming respiratory barrier; protected by US Patent 11,517,523 and international patents.
Company scaling production, pursuing regulatory discussions in US, UK, Australia, and targets commercial rollout in select markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.